LPCN - Lipocine Inc Stock Price, Fair Value and News

5.80USD+0.05 (+0.87%)Delayed as of 17 May 2024, 10:05 am ET

Market Summary

USD5.80+0.05

Delayedas of 17 May 2024, 10:05 am

0.87%

LPCN Stock Price

View Fullscreen

LPCN RSI Chart

LPCN Valuation

Market Cap

30.8M

Price/Earnings (Trailing)

-3.43

Price/Sales (Trailing)

10.39

EV/EBITDA

-3.1

Price/Free Cashflow

-5.55

LPCN Price/Sales (Trailing)

LPCN Profitability

EBT Margin

-302.87%

Return on Equity

-37.44%

Return on Assets

-35.24%

Free Cashflow Yield

-18.01%

LPCN Fundamentals

LPCN Revenue

Revenue (TTM)

3.0M

LPCN Earnings

Earnings (TTM)

-9.0M

Earnings Growth (Yr)

190.79%

Earnings Growth (Qtr)

253.95%

Breaking Down LPCN Revenue

52 Week Range

2.765.94

(Low)(High)

Last 7 days

9.7%

Last 30 days

20.8%

Last 90 days

43.4%

Trailing 12 Months

58.8%

How does LPCN drawdown profile look like?

LPCN Financial Health

Current Ratio

16.99

Debt/Equity

0.06

Debt/Cashflow

-3.83

LPCN Investor Care

Shares Dilution (1Y)

2.72%

Diluted EPS (TTM)

-1.76

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	1.3M	2.1M	0	3.0M
2022	0	10.9M	5.7M	500.0K
2021	0	0	8.2M	16.1M
2019	0	0	165.0K	165.0K
2018	4.1M	428.0K	428.0K	428.0K
2012	0	4.6M	6.2M	7.7M
2011	0	0	0	3.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Lipocine Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 08, 2024	fogarty krista	acquired	-	-	991	principal accounting officer
Mar 08, 2024	patel mahesh v.	acquired	-	-	4,893	ceo and president
May 25, 2023	patel mahesh v.	bought	43,791	5.03	8,706	ceo and president
Mar 24, 2023	patel mahesh v.	bought	48,000	0.32	150,000	ceo and president
Mar 20, 2023	ono richard dana	bought	1,360	0.34	4,000	-
Mar 17, 2023	patel mahesh v.	bought	16,500	0.33	50,000	ceo and president
Nov 22, 2022	papapetropoulos spyros	bought	10,217	0.47	21,739	-
Nov 14, 2022	patel mahesh v.	bought	29,250	0.39	75,000	ceo and president
Sep 27, 2022	patel mahesh v.	bought	41,000	0.41	100,000	ceo and president
May 17, 2022	fogarty krista	bought	10,750	0.86	12,500	principal accounting officer

Which funds bought or sold LPCN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	STATE STREET CORP	unchanged	-	45,447	96,855	-%
May 15, 2024	MORGAN STANLEY	unchanged	-	1,740	3,754	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-16.00	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-10.01	4,229	10,473	-%
May 15, 2024	TWO SIGMA ADVISERS, LP	reduced	-1.91	60,595	133,754	-%
May 15, 2024	Royal Bank of Canada	reduced	-84.62	-	-	-%
May 14, 2024	OLD POINT TRUST & FINANCIAL SERVICES N A	new	-	307	307	-%
May 13, 2024	FMR LLC	sold off	-100	-248	-	-%
May 13, 2024	Tidemark, LLC	unchanged	-	142	307	-%
May 13, 2024	UBS Group AG	new	-	2,241	2,241	-%

Are Funds Buying or Selling LPCN?

Are funds buying LPCN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own LPCN

No. of Funds

Unveiling Lipocine Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 11, 2021	renaissance technologies llc	0.00%	0	SC 13G/A
Feb 10, 2021	hudson bay capital management lp	0%	0	SC 13G/A
Feb 10, 2021	vanguard group inc	5.47%	3,591,004	SC 13G
Jan 05, 2021	sabby management, llc	12.%	0	SC 13G/A
Feb 25, 2020	sabby management, llc	7.04%	3,361,344	SC 13G
Feb 12, 2020	renaissance technologies llc	5.36%	1,901,256	SC 13G
Feb 06, 2020	hudson bay capital management lp	9.99%	3,932,593	SC 13G
Jan 14, 2020	sabby management, llc	4.99%	1,770,341	SC 13G/A
Nov 22, 2019	sabby management, llc	8.74%	3,100,000	SC 13G

Recent SEC filings of Lipocine Inc

View All Filings

Date Filed	Form Type	Document
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
May 08, 2024	8-K	Current Report
May 01, 2024	8-K	Current Report
Apr 29, 2024	8-K	Current Report
Apr 26, 2024	424B5	Prospectus Filed
Apr 26, 2024	8-K	Current Report
Apr 25, 2024	EFFECT	EFFECT
Apr 23, 2024	S-3/A	S-3/A
Apr 23, 2024	DEF 14A	DEF 14A

Peers (Alternatives to Lipocine Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	27.86%	5.69%	-8.52	7.43	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.1B	2.0B	3.08%	-21.73%	-57.61	9.55	75.20%	68.82%
BMRN	14.6B	2.5B	-15.33%	-16.61%	71.11	5.91	13.74%	186.89%
INCY	12.8B	3.8B	6.86%	-11.90%	17.13	3.39	8.58%	129.81%
MID-CAP
BBIO	5.8B	107.9M	23.06%	120.60%	-10.63	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-18.99%	-52.96%	-12.22	9.73	394.93%	39.61%
AXSM	3.7B	251.0M	12.53%	-1.35%	-12.4	14.64	73.58%	-86.73%
ARWR	3.1B	240.7M	5.66%	-32.59%	-6.6	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.11%	-34.57%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
NVAX	2.0B	996.6M	260.65%	85.68%	-5.07	2.03	-26.66%	65.49%
CPRX	1.9B	411.3M	5.34%	30.65%	29.69	4.7	60.38%	-34.49%
CRBP	489.5M	881.7K	11.38%	343.80%	-14.5	481.06	-77.61%	33.36%
INO	330.9M	4.9M	32.47%	47.80%	-2.65	67.99	-54.97%	48.23%
IBIO	15.7M	2.1M	-6.67%	89.09%	-0.68	7.61	-13.45%	69.54%

Lipocine Inc News

Latest updates

Lipocine Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2021Q4	2021Q3	2019Q4	2019Q3	2018Q4	2018Q3	2018Q2	2018Q1	2012Q4	2012Q3	2012Q2	2011Q4
Revenue	33.3%	7,617,174	5,712,881	3,808,587	1,904,294	-	-	500,000	333,333	166,667	-	164,990	-	-	-	428,031	1.00	-	-	-
Operating Expenses	56.4%	4,394,645	2,809,540	3,955,605	4,393,623	2,560,833	2,899,371	4,027,531	3,301,897	3,588,667	3,448,252	3,140,678	3,171,368	2,353,056	3,164,409	-	-	-	-	-
S&GA Expenses	-100.0%	-	1,134,608	1,440,394	1,287,313	890,343	798,939	1,129,519	1,048,086	1,222,146	1,607,425	1,427,261	989,484	930,137	1,682,031	1,687,490	-	-	-	-
R&D Expenses	68.3%	2,818,926	1,674,932	2,515,211	3,106,310	1,670,491	2,100,432	2,898,012	2,253,811	2,366,521	1,840,827	1,713,417	2,181,885	1,422,919	1,482,378	-	-	-	-	-
EBITDA Margin	45.3%	-3.02	-5.51	-5.61	-8.41	-21.44	0.73	0.32	-0.03	-2.15	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	0.50	7,568	32,052	44,839	154,881	183,500	-88,995	218,577	211,494	192,466	-	-	-	-
Income Taxes	-64.0%	200	555	-	200	481	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	254.0%	3,513,821	-2,281,698	-3,548,629	-3,870,030	-2,229,432	-2,409,165	-2,631,777	12,624,021	-3,081,297	-3,292,075	-3,060,200	-3,225,479	-2,459,072	-3,255,500	-	-	-	-	-
EBT Margin	45.2%	-3.03	-5.52	-5.63	-8.44	-21.52	0.72	0.31	-0.04	-2.18	-	-	-	-	-	-	-	-	-	-
Net Income	254.0%	3,513,621	-2,282,253	-3,548,629	-3,870,230	-2,229,913	-2,409,165	-2,631,777	12,624,021	-3,081,297	-3,292,075	-3,060,200	-3,225,478	-2,459,072	-3,255,500	-	-	-	-	-
Net Income Margin	45.2%	-3.03	-5.52	-5.63	-8.44	-21.52	0.72	0.31	-0.04	-2.18	-	-	-	-	-	-	-	-	-	-
Free Cashflow	218.5%	2,407,519	-2,031,472	-3,309,597	-3,932,057	-1,935,646	-3,198,174	-3,056,631	8,994,540	-6,980,787	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	10.6%	25,447	23,001	24,752	30,483	34,022	37,543	39,424	42,193	47,604	52,482	40,389	47,179	50,577	25,353	24,752	23,485	20,992	19,658	17,342	19,677	22,989
Current Assets	10.7%	25,315	22,861	24,614	27,085	30,615	34,135	36,111	38,080	43,498	46,380	40,365	47,156	45,944	25,329	24,727	23,460	20,965	19,631	17,311	19,642	22,950
Cash Equivalents	-35.4%	3,081	4,772	4,073	5,015	4,769	3,148	2,397	4,981	5,733	2,951	4,517	10,968	15,602	19,217	12,938	13,838	20,135	14,729	11,665	8,664	8,222
Net PPE	-7.3%	108	116	115	123	131	132	37.00	40.00	32.00	7.00	-	-	-	-	1.00	2.00	3.00	4.00	7.00	11.00	15.00
Liabilities	-43.4%	1,490	2,632	2,271	1,931	2,062	1,908	1,775	2,304	5,194	6,912	7,578	11,434	8,186	10,011	10,243	10,400	14,439	13,370	9,837	9,827	10,437
Current Liabilities	-43.4%	1,490	2,632	2,241	1,827	1,930	1,678	1,511	1,713	3,520	5,617	6,433	8,808	5,397	6,584	5,789	4,232	4,060	4,965	5,235	4,443	4,277
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	1,442	2,257	3,151	4,002	4,688	3,814	4,602	5,384	6,160
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	1,442	2,257	3,151	4,002	4,688	3,814	4,602	5,384	6,160
Shareholder's Equity	17.6%	23,956	20,369	22,482	28,552	31,960	35,635	37,649	39,890	42,410	45,570	32,811	35,746	42,391	15,342	14,508	13,085	6,553	6,288	7,505	9,850	12,552
Retained Earnings	1.8%	-196,263	-199,777	-197,494	-190,843	-187,295	-183,425	-181,195	-178,785	-176,154	-172,666	-185,290	-182,209	-175,400	-172,032	-167,520	-163,207	-156,837	-151,067	-147,775	-144,714	-141,284
Additional Paid-In Capital	0.0%	220,262	220,171	220,023	219,444	219,284	219,112	218,953	218,792	218,663	218,286	218,137	217,987	217,845	187,408	182,063	176,327	163,427	157,392	155,318	154,600	153,873
Accumulated Depreciation	0.7%	1,191	1,182	1,174	1,166	1,158	1,154	1,151	1,148	1,146	1,144	-	-	-	1,144	1,143	1,142	1,141	1,140	1,136	1,132	1,129
Shares Outstanding	0%	5,316	5,316	5,316	5,235	5,207	5,235	5,235	5,234	5,195	5,194	5,087	5,194	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	25,600	-	-	-	69,200	-	-	-	120,500	-	-	-	72,000	-	-	-	43,400	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	219.0%	2,408	-2,022	-2,606	-3,309	-3,928	-1,838	-3,198	-3,046	-3,885	8,995	-6,980	-2,363	-4,061	-3,684	-4,163	-4,079	-3,376	-3,308	-2,797	-2,557	-3,002
Share Based Compensation	-35.4%	99.00	154	158	165	178	165	160	140	171	155	155	147	148	235	352	465	322	254	58.00	446	277
Cashflow From Investing	-250.0%	-4,089	2,727	1,243	3,560	5,555	2,596	614	3,788	7,295	-9,722	1,368	-1,431	-33,994	5,408	-1,398	-4,019	3,902	557	5,971	-1,447	-2,082
Cashflow From Financing	-52.9%	-8.10	-5.30	421	-5.20	-6.02	-5.90	44*	-1,493	-627	-838	-838	-838	29,440	4,555	4,662	6,801	4,880	5,815	-173	-552	5,230

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

LPCN Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
License revenue	$ 7,500,000	$ 54,990
Royalty revenue	117,174
Total revenues	7,617,174	54,990
Operating expenses:
Research and development	2,818,926	3,106,310
General and administrative	1,575,719	1,287,313
Total operating expenses	4,394,645	4,393,623
Operating income (loss)	3,222,529	(4,338,633)
Other income (expense):
Interest and investment income	331,364	370,469
Unrealized gain (loss) on warrant liability	(40,072)	98,134
Total other income, net	291,292	468,603
Income (loss) before income tax expense	3,513,821	(3,870,030)
Income tax expense	(200)	(200)
Net income (loss)	3,513,621	(3,870,230)
Issuance of Series B preferred stock dividend		(89)
Net income (loss) attributable to common shareholders	$ 3,513,621	$ (3,870,319)
Basic income (loss) per share attributable to common stock	$ 0.66	$ (0.74)
Weighted average common shares outstanding, basic	5,315,830	5,234,830
Diluted income (loss) per share attributable to common stock	$ 0.66	$ (0.76)
Weighted average common shares outstanding, diluted	5,357,530	5,234,830
Comprehensive loss:
Net income (loss)	$ 3,513,621	$ (3,870,319)
Net unrealized gain (loss) on marketable investment securities	(17,863)	23,562
Comprehensive income (loss)	$ 3,495,758	$ (3,846,757)

LPCN Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 3,081,337	$ 4,771,758
Marketable investment securities	21,550,661	17,263,788
Accrued interest income	100,134	52,254
Prepaid and other current assets	583,087	773,424
Total current assets	25,315,219	22,861,224
Property and equipment, net of accumulated depreciation of $1,190,703 and $1,182,191 respectively	107,583	116,095
Other assets	23,753	23,753
Total assets	25,446,555	23,001,072
Current liabilities:
Accounts payable	671,445	1,395,977
Accrued expenses	761,465	1,218,486
Warrant liability	57,238	17,166
Total current liabilities	1,490,148	2,631,629
Total liabilities	1,490,148	2,631,629
Commitments and contingencies (notes 7, 8, 9 and 10)
Stockholders’ equity:
Common stock, par value $0.0001 per share, 200,000,000 shares authorized; 5,316,166 issued and 5,315,830 outstanding	8,860	8,860
Additional paid-in capital	220,262,456	220,171,250
Treasury stock at cost, 336 shares	(40,712)	(40,712)
Accumulated other comprehensive gain (loss)	(10,604)	7,259
Accumulated deficit	(196,263,593)	(199,777,214)
Total stockholders’ equity	23,956,407	20,369,443
Total liabilities and stockholders’ equity	$ 25,446,555	$ 23,001,072

About Lipocine Inc

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include LPCN 1154 for postpartum depression; LPCN 2101 for women with epilepsy; and LPCN 1148, a novel prodrug of testosterone, testosterone laurate for the management of decompensated cirrhosis. It also develops LPCN 1144, an oral prodrug of androgen receptor modulator for the treatment of non-cirrhotic non-alcoholic steatohepatitis, which has completed Phase II testing; LPCN 1111, an oral TRT product of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical testing; and LPCN 1107, an oral hydroxy progesterone caproate product for the prevention of recurrent preterm birth. Lipocine Inc. was founded in 1997 and is headquartered in Salt Lake City, Utah.

CEO	Dr. Mahesh V. Patel Ph.D.
WEBSITE	lipocine.com
INDUSTRY	Biotechnology
EMPLOYEES	15

Lipocine Inc Frequently Asked Questions

What is the ticker symbol for Lipocine Inc? What does LPCN stand for in stocks?

LPCN is the stock ticker symbol of Lipocine Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Lipocine Inc (LPCN)?

As of Thu May 16 2024, market cap of Lipocine Inc is 30.75 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LPCN stock?

You can check LPCN's fair value in chart for subscribers.

What is the fair value of LPCN stock?

You can check LPCN's fair value in chart for subscribers. The fair value of Lipocine Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Lipocine Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LPCN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Lipocine Inc a good stock to buy?

The fair value guage provides a quick view whether LPCN is over valued or under valued. Whether Lipocine Inc is cheap or expensive depends on the assumptions which impact Lipocine Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LPCN.

What is Lipocine Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, LPCN's PE ratio (Price to Earnings) is -3.43 and Price to Sales (PS) ratio is 10.39. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LPCN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Lipocine Inc's stock?

In the past 10 years, Lipocine Inc has provided -0.017 (multiply by 100 for percentage) rate of return.